Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

Journal of the American College of Cardiology

Volumn 71, Issue 13, 2018, Pages 1474-1482

  Messerli, Franz H ^a,b   Bangalore, Sripal ^c   Bavishi, Chirag ^d   Rimoldi, Stefano F ^a  

^a BERN UNIVERSITY HOSPITAL   (Switzerland)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Mount Sinai St Luke's and Mount Sinai West Hospitals   (United States)

Author keywords

adverse events; angioedema; angiotensin receptor blocker; blood pressure; chronic kidney disease; coronary heart disease; cough; diabetes; heart failure; hypertension; left ventricular hypertrophy

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ALL CAUSE MORTALITY; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CORONARY ARTERY DISEASE; COUGHING; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK BENEFIT ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DRUG EFFECT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOEDEMA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

EID: 85044065887     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.01.058     Document Type: Review

References (56)

1. Bacon Francis. Novum Organum Scientiarum. 1620.
2. Chobanian, A.V., Editorial: Angiotensin inhibition. N Engl J Med 291 (1974), 844–845.
3. Haber, E., Renin inhibitors. N Engl J Med 298 (1978), 1023–1025.
4. Messerli, F.H., Weber, M.A., Brunner, H.R., Angiotensin II receptor inhibition: a new therapeutic principle. Arch Intern Med 156 (1996), 1957–1965.
5. Messerli, F.H., Bangalore, S., Antihypertensive efficacy of aliskiren: is hydrochlorothiazide an appropriate benchmark?. Circulation 119 (2009), 371–373.
6. Musini, V.M., Fortin, P.M., Bassett, K., Wright, J.M., Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev(4), 2008, CD007066.
7. Heran, B.S., Wong, M.M., Heran, I.K., Wright, J.M., Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. Cochrane Database Syst Rev(4), 2008, CD003823.
8. Heran, B.S., Wong, M.M., Heran, I.K., Wright, J.M., Blood pressure lowering efficacy of angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev(4), 2008, CD003822.
9. Messerli, F.H., Makani, H., Benjo, A., Romero, J., Alviar, C., Bangalore, S., Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol 57 (2011), 590–600.
10. Bonner, G., Bakris, G.L., Sica, D., et al. Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril. J Hum Hypertens 27 (2013), 479–486.
11. Ruilope, L.M., SEVITENSION Study Investigators. Fixed-combination olmesartan/amlodipine was superior to perindopril + amlodipine in reducing central systolic blood pressure in hypertensive patients with diabetes. J Clin Hypertens (Greenwich) 18 (2016), 528–535.
12. Omboni, S., Malacco, E., Mallion, J.M., Volpe, M., Zanchetti, A., Study Group. Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies. J Hypertens 30 (2012), 1468–1477.
13. Law, M.R., Wald, N.J., Morris, J.K., Jordan, R.E., Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326, 2003, 1427.
14. Klingbeil, A.U., Schneider, M., Martus, P., Messerli, F.H., Schmieder, R.E., A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115 (2003), 41–46.
15. Xu, R., Sun, S., Huo, Y., et al. Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials. Medicine (Baltimore), 94, 2015, e1560.
16. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf, S., Sleight, P., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000), 145–153.
17. Nissen, S.E., Tuzcu, E.M., Libby, P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292 (2004), 2217–2225.
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002), 2981–2997.
19. Potier, L., Roussel, R., Elbez, Y., et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103 (2017), 1339–1346.
20. Li, E.C., Heran, B.S., Wright, J.M., Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension. Cochrane Database Syst Rev(8), 2014, CD009096.
21. Bangalore, S., Fakheri, R., Toklu, B., Ogedegbe, G., Weintraub, H., Messerli, F.H., Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc 91 (2016), 51–60.
22. Ricci, F., Di Castelnuovo, A., Savarese, G., Perrone Filardi, P., De Caterina, R., ACE-inhibitors versus angiotensin receptor blockers for prevention of events in cardiovascular patients without heart failure: a network meta-analysis. Int J Cardiol 217 (2016), 128–134.
23. Bangalore, S., Kumar, S., Wetterslev, J., Messerli, F.H., Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ, 342, 2011, d2234.
24. Messerli, F.H., Bangalore, S., Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation 135 (2017), 2085–2087.
25. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316 (1987), 1429–1435.
26. McMurray, J.J., Ostergren, J., Swedberg, K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003), 767–771.
27. Granger, C.B., McMurray, J.J., Yusuf, S., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003), 772–776.
28. Burnett, H., Earley, A., Voors, A.A., et al. Thirty years of evidence on the efficacy of drug treatments for chronic heart failure with reduced ejection fraction: a network meta-analysis. Circ Heart Fail, 10, 2017, e003529.
29. Packer, M., McMurray, J.J.V., Importance of endogenous compensatory vasoactive peptides in broadening the effects of inhibitors of the renin-angiotensin system for the treatment of heart failure. Lancet 389 (2017), 1831–1840.
30. Messerli, F.H., Rimoldi, S.F., Bangalore, S., The transition from hypertension to heart failure: contemporary update. J Am Coll Cardiol HF 5 (2017), 543–551.
31. Mann, J.F., Schmieder, R.E., McQueen, M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008), 547–553.
32. Xie, X., Liu, Y., Perkovic, V., et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67 (2016), 728–741.
33. Lin, C.C., Wu, Y.T., Yang, W.C., et al. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: a nationwide study of therapy with renin-angiotensin system blockade. PLoS One, 12, 2017, e0189126.
34. Barnett, A.H., Bain, S.C., Bouter, P., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004), 1952–1961.
35. Catala-Lopez, F., Macias Saint-Gerons, D., Gonzalez-Bermejo, D., et al. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLoS Med, 13, 2016, e1001971.
36. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant Subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf, S., Teo, K., et al. Effects of the angiotensin-receptor blocker j telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372 (2008), 1174–1183.
37. Yusuf, S., Diener, H.C., Sacco, R.L., et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 359 (2008), 1225–1237.
38. Bavishi, C., Ahmed, M., Trivedi, V., et al. Meta-analysis of randomized trials on the efficacy and safety of angiotensin-converting enzyme inhibitors in patients ≥65 years of age. Am J Cardiol 118 (2016), 1427–1436.
39. Bangalore, S., Kumar, S., Messerli, F.H., Angiotensin-converting enzyme inhibitor associated cough: deceptive information from the Physicians’ Desk Reference. Am J Med 123 (2010), 1016–1030.
40. McDowell, S.E., Coleman, J.J., Ferner, R.E., Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332 (2006), 1177–1181.
41. Tseng, D.S., Kwong, J., Rezvani, F., Coates, A.O., Angiotensin-converting enzyme-related cough among Chinese-Americans. Am J Med 123 (2010), 183.e11–183.e15.
42. Su, M., Zhang, Q., Bai, X., et al. Availability, cost, and prescription patterns of antihypertensive medications in primary health care in China: a nationwide cross-sectional survey. Lancet 390 (2017), 2559–2568.
43. Makani, H., Messerli, F.H., Romero, J., et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 110 (2012), 383–391.
44. Israili, Z.H., Hall, W.D., Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy:a review of the literature and pathophysiology. Ann Intern Med 117 (1992), 234–242.
45. Brown, N.J., Snowden, M., Griffin, M.R., Recurrent angiotensin-converting enzyme inhibitor–associated angioedema. JAMA 278 (1997), 232–233.
46. Messerli, F.H., Nussberger, J., Vasopeptidase inhibition and angio-oedema. Lancet 356 (2000), 608–609.
47. Banerji, A., Blumenthal, K.G., Lai, K.H., Zhou, L., Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record. J Allergy Clin Immunol Pract 5 (2017), 744–749.
48. Kostis, J.B., Kim, H.J., Rusnak, J., et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 165 (2005), 1637–1642.
49. Agostoni, A., Cicardi, M., Cugno, M., Zingale, L.C., Gioffre, D., Nussberger, J., Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 44 (1999), 21–25.
50. Slater, E.E., Merrill, D.D., Guess, H.A., et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 260 (1988), 967–970.
51. Grossman, E., Messerli, F.H., Neutel, J.M., Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?. Arch Intern Med 160 (2000), 1905–1911.
52. Dean, D.E., Schultz, D.L., Powers, R.H., Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 46 (2001), 1239–1243.
53. Thomopoulos, C., Parati, G., Zanchetti, A., Effects of blood-pressure-lowering treatment in hypertension: 9. Discontinuations for adverse events attributed to different classes of antihypertensive drugs: meta-analyses of randomized trials. J Hypertens 34 (2016), 1921–1932.
54. ONTARGET Investigators, Yusuf, S., Teo, K.K., et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358 (2008), 1547–1559.
55. Hansson, L., Smith, D.H., Reeves, R., Lapuerta, P., Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. Arch Intern Med 160 (2000), 1654–1658.
56. Messerli, F.H., Bangalore, S., Rimoldi, S.F., Gasowski, J., Nussberger, J., Are ACE inhibitors acceptable ingredients in polypills?. Lancet, 390, 2017, 26.